Home › U.S. FDA panel: data support safety, efficacy of Merck allergy drug
 

Keywords :   


U.S. FDA panel: data support safety, efficacy of Merck allergy drug

2014-01-28 23:10:31| Biotech - Topix.net

Merck & Co's experimental allergy drug, Ragwitek, appears safe and effective for use in patients between the ages of 18 and 65, a panel of advisors to the U.S. Food and Drug Administration concluded on Tuesday.

Tags: support data safety panel

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.05Tom Hardy Is Jo Malone Londons New Ambassador for Cypress & Grapevine Cologne Intense
15.05Mooncat Introduces New Hue, Holds Bi-Annual Sale
15.05Eastern North Pacific Tropical Weather Outlook
15.05European Wax Center\'s EWC Treat Brightening Ingrown Hair Wipes Awarded
15.05EchoStar pay TV subscribers down 348,000 in 1Q 2024
15.05Atlantic Tropical Weather Outlook
15.05PBE Makes Investment in Plus-Size Adult Incontinence Products
15.05Flint Group retains EcoVadis Silver Medal for 2024
More »